Premium
Assessment of early paraprotein response to vincristine‐doxorubicin‐dexamethasone chemotherapy may help guide therapy in multiple myeloma
Author(s) -
Ross D. M.,
To L. B.,
Horvath N.
Publication year - 2004
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/j.1445-5994.2004.00689.x
Subject(s) - medicine , vincristine , dexamethasone , multiple myeloma , chemotherapy , doxorubicin , oncology , monoclonal , autologous stem cell transplantation , cyclophosphamide , immunology , monoclonal antibody , antibody
Vincristine, doxorubicin and dexamethasone (VAD) are commonly used as the initial chemotherapy in myeloma patients prior to high‐dose therapy and autologous stem cell transplantation. We reviewed monoclonal protein responses and survival of 62 patients treated in this way. Among patients with IgG paraprotein, achievement of at least 50% reduction in paraprotein after the first cycle of VAD correlated with significantly better event‐free survival at 3 years, compared with those having less than 50% response. We postulate that early paraprotein response may be used to identify high risk patients. (Intern Med J 2004; 34: 576−578)